DOCSLIB.ORG

Walgreens Boots Alliance, Inc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Walgreens Boots Alliance, Inc WALGREENS BOOTS ALLIANCE, INC. FORM 10-K (Annual Report) Filed 10/25/17 for the Period Ending 08/31/17 Address 108 WILMOT ROAD DEERFIELD, IL, 60015 Telephone (847) 315-2500 CIK 0001618921 Symbol WBA SIC Code 5912 - Retail-Drug Stores and Proprietary Stores Fiscal Year 08/31 http://www.edgar-online.com © Copyright 2017, EDGAR Online, a division of Donnelley Financial Solutions. All Rights Reserved. Distribution and use of this document restricted under EDGAR Online, a division of Donnelley Financial Solutions, Terms of Use. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2017 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From ____________ to ___________ Commission file number 001-36759 WALGREENS BOOTS ALLIANCE, INC . (Exact name of registrant as specified in its charter) Delaware 47-1758322 (State of incorporation) (I.R.S. Employer Identification No.) 108 Wilmot Road, Deerfield, Illinois 60015 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (847) 315-2500 Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common Stock ($.01 Par Value) The NASDAQ Stock Market LLC 2.875% Notes due 2020 New York Stock Exchange 3.600% Notes due 2025 New York Stock Exchange 2.125% Notes due 2026 New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days. Yes ☒No ☐ Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one): Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to the Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ As of February 28, 2017, the aggregate market value of Walgreens Boots Alliance, Inc. common stock held by non-affiliates (based upon the closing transaction price on such date) was approximately $80.7 billion. As of September 30, 2017, there were 1,009,549,218 shares of Walgreens Boots Alliance, Inc. common stock outstanding. DOCUMENTS INCORPORATED BY REFERENCE Portions of the definitive proxy statement for our Annual Meeting of Stockholders planned to be held on January 17, 2018 are incorporated by reference into Part III of this Form 10-K as indicated herein. Table of Contents Walgreens Boots Alliance, Inc. Annual Report on Form 10-K Table of Contents Part I Page Item 1. Business 1 Item 1A. Risk factors 9 Item 1B. Unresolved staff comments 26 Item 2. Properties 26 Item 3. Legal proceedings 27 Item 4. Mine safety disclosures 27 Executive officers of the registrant 28 Part II Item 5. Market for registrant’s common equity, related stockholder matters and issuer purchases of equity securities 29 Item 6. Selected financial data 31 Item 7. Management’s discussion and analysis of financial condition and results of operations 33 Item 7A. Qualitative and quantitative disclosures about market risk 55 Item 8. Financial statements and supplementary data 63 Item 9. Changes in and disagreements with accountants on accounting and financial disclosure 105 Item 9A. Controls and procedures 105 Item 9B. Other information 105 Part III Item 10. Directors, executive officers and corporate governance 106 Item 11. Executive compensation 106 Item 12. Security ownership of certain beneficial owners and management and related stockholder matters 106 Item 13. Certain relationships and related transactions and director independence 106 Item 14. Principal accounting fees and services 106 Part IV Item 15. Exhibits and financial statement schedules 106 Item 16. Form 10-K summary 115 Signatures 116 On December 31, 2014, Walgreens Boots Alliance, Inc. became the successor of Walgreen Co. (“Walgreens”) pursuant to a merger to effect a reorganization of Walgreens into a holding company structure (the “Reorganization”), with Walgreens Boots Alliance, Inc. becoming the parent holding company. References in this Annual Report on Form 10-K (this “Form 10-K”) to the “Company,” “we,” “us” or “our” refer to Walgreens Boots Alliance, Inc. and its subsidiaries from and after the effective time of the Reorganization on December 31, 2014 and, prior to that time, to the predecessor registrant Walgreens and its subsidiaries, and in each case do not include unconsolidated partially-owned entities, except as otherwise indicated or the context otherwise requires. Our fiscal year ends on August 31, and references herein to “fiscal 2017 ” refer to our fiscal year ended August 31, 2017 . This Form 10-K includes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. See cautionary note regarding forward-looking statements in management’s discussion and analysis of financial condition and results of operations in part II, item 7 below. All trademarks, trade names and service marks used herein are the property of their respective owners. Table of Contents PART I Item 1. Business Overview Walgreens Boots Alliance, Inc., a Delaware corporation (“Walgreens Boots Alliance”) is the first global, pharmacy-led health and wellbeing enterprise with sales of $118.2 billion in the fiscal year ended August 31, 2017 . Our purpose is to help people across the world lead healthier and happier lives. Walgreens Boots Alliance is the largest retail pharmacy, health and daily living destination across the U.S. and Europe. Walgreens Boots Alliance and the companies in which it has equity method investments together have a presence in more than 25 1 countries and employ more than 385,000 1 people. The company is a global leader in pharmacy-led, health and wellbeing retail and, together with the companies in which it has equity method investments, has over 13,200 1 stores in 11 1 countries as well as one of the largest global pharmaceutical wholesale and distribution networks, with over 390 1 distribution centers delivering to more than 230,000 2 pharmacies, doctors, health centers and hospitals each year in more than 20 1 countries. In addition, Walgreens Boots Alliance is one of the world’s largest purchasers of prescription drugs and many other health and wellbeing products. Our portfolio of retail and business brands includes Walgreens, Duane Reade, Boots and Alliance Healthcare, as well as increasingly global health and beauty product brands, such as No7, Soap & Glory, Liz Earle, Sleek MakeUP and Botanics. Our global brands portfolio is enhanced by our in-house product research and development capabilities. We seek to further drive innovative ways to address global health and wellness challenges. We believe we are well positioned to expand customer offerings in existing markets and become a health and wellbeing partner of choice in emerging markets. Walgreens Boots Alliance was incorporated in Delaware in 2014 and, as described below, is the successor of Walgreen Co., an Illinois corporation, which was formed in 1909 as a successor to a business founded in 1901. Our principal executive offices are located at 108 Wilmot Road, Deerfield, Illinois 60015. Our common stock trades on the NASDAQ Stock Market under the symbol “WBA”. 1 As of August 31, 2017 , using publicly available information for AmerisourceBergen. 2 For 12 months ending August 31, 2017 , using publicly available information for AmerisourceBergen. - 1 - Table of Contents Recent transactions On March 31, 2017, Walgreens Boots Alliance and pharmacy benefit manager Prime Therapeutics LLC closed a transaction to form a combined central specialty pharmacy and mail services company, AllianceRx Walgreens Prime, as part of a strategic alliance. AllianceRx Walgreens Prime is consolidated by Walgreens Boots Alliance and reported within the Retail Pharmacy USA division in its financial statements. See note 6, acquisitions to the Consolidated Financial Statements for further information.
Load more

Recommended publications
  • ANGEBOTSUNTERLAGE Freiwilliges Öffentliches
    Pflichtveröffentlichung gemäß §§ 34, 14 Abs. 2 und 3 Wertpapiererwerbs- und Übernahmegesetz (WpÜG) Aktionäre der WMF Württembergische Metallwarenfabrik Aktiengesellschaft, insbesondere mit Wohnsitz, Sitz oder gewöhnlichem Aufenthalt außerhalb der Bundesrep ublik Deutschland, sollten die Hinweise in Abschnitt 1 "Allgemeine Hinweise, insbesondere für Aktionäre mit Wohnsitz, Sitz oder gewöhnlichem Aufenthalt außerhalb der Bundesrepublik Deutschland" auf den Seiten 4 ff. dieser Angebotsunterlage sowie in Abschnitt 23 "Wichtige Hinweise für US-Aktionäre" auf den Sei- ten 48 ff. dieser Angebotsunterlage besonders beachten. ANGEBOTSUNTERLAGE Freiwilliges öffentliches Übernahmeangebot (Barangebot) der Finedining Capital GmbH Leopoldstraße 8-10, 80802 München, Deutschland an die Aktionäre der WMF Württembergische Metallwarenfabrik Aktiengesellschaft Eberhardstraße 17-47, 73309 Geislingen an der Steige, Deutschland zum Erwerb ihrer auf den Inhaber lautenden Stammaktien und ihrer auf den Inhaber lautenden Vor- zugsaktien an der WMF Württembergische Metallwarenfabrik Aktiengesellschaft gegen Zahlung einer Geldleistung in Höhe von EUR 47,00 je Stammaktie und EUR 31,80 je Vorzugsaktie der WMF Württembergische Metallwarenfabrik Aktiengesellschaft Die Annahmefrist läuft vom 16. August 2012 bis 20. September 2012, 24:00 Uhr (Ortszeit Frankfurt am Main) / 18:00 Uhr (Ortszeit New York) Aktien der WMF Württembergische Metallwarenfabrik Aktiengesellschaft: International Securities Identification Number (ISIN) DE0007803009 (Stammaktien) und DE0007803033 (Vorzugsaktien)
    [Show full text]
  • Helping People Look and Feel Their Best Alliance Boots Annual Report 2013/14 We Are a Leading International Pharmacy-Led Health and Beauty Group
    Alliance Boots Alliance Annual Report 2013/14 Report Annual Helping people look and feel their best Alliance Boots Annual Report 2013/14 We are a leading international pharmacy-led health and beauty group. Our focus is on helping people look and feel their best. What’s inside Strategic review Our financial performance in 2013/14 01 Executive Chairman’s statement 02 Our mission, purpose and values 05 Our Group at a glance 06 Our business activities 08 Group strategy and objectives 10 Our markets and business environment 14 Our financial record 16 Business review: Overview 18 Health & Beauty Division 20 Pharmaceutical Wholesale Division 28 Other activities 34 Financial review 36 Performance measures 42 We are launching innovative Our people 43 new products tailored to meet Corporate social responsibility 46 customer needs page 12 Governance Boots much loved brands are Board of Directors 50 increasingly available across Board report on corporate governance 54 the world page 26 Board report on remuneration 56 Audit and risk committee report 59 Risk management 60 Consolidated financial statements Directors’ responsibilities statement 62 Statutory auditor’s report 63 Group income statement 64 Group statement of comprehensive income 64 Group statement of financial position 65 Group statement of changes in equity 66 Group statement of cash flows 67 Notes to the consolidated financial statements 68 Additional information Principal businesses, associates and joint ventures 120 Glossary of key terms 123 Alphega is expanding its Supporting the fight against pharmacy network cancer page 44 across Europe page 32 Alliance Boots | Annual Report 2013/14 01 Strategic review Our financial performance in 2013/14 Strategic review for the year ended 31 March 2014 Underlying profit attributable to equity shareholders increased by 18.5%.
    [Show full text]
  • At the Heart of Health Corporate Social Responsibility Report
    2020 At the Heart of Health Corporate Social Responsibility Report #WeAreWBA We are a leading global pharmacy retailer and wholesaler. As a health and well-being enterprise our purpose is to help people across the world lead healthier and happier lives. At the Heart of Health is our annual Corporate Social Responsibility report, covering our CSR initiatives, sustainability progress and Environmental, Social and Governance (ESG) performance for the fiscal year ended Aug. 31, 2020. OVERVIEW HEALTHY PLANET Message from Our Leaders 4 Energy and Emissions 85 Q&A with Our CSR Committee Chair 6 Waste and Plastics 94 Our Vision, Purpose and Values 8 Case Study: Honeybees on Campus 100 At a Glance: WBA 9 SUSTAINABLE MARKETPLACE Highlights and Recognitions 10 Progress Dashboard 12 Sustainability Progress in Our Owned Brands 103 Our Approach to CSR 15 Sourcing 106 CSR Materiality 24 Ingredients, Materials and Traceability 111 Stakeholder Engagement 28 Packaging, Labeling and Transparency 114 Our Response to COVID-19 38 Case Study: Removing Plastics from Boots UK Gift Product Lines 117 Our Response to the Racial Equity Movement 46 Brands with Purpose 118 HEALTHY AND INCLUSIVE WORKPLACE HEALTHY COMMUNITIES Employee Health, Well-being and Safety 123 Access to Affordable and Quality Healthcare 51 Equal Opportunities 134 Health Education and Awareness 61 Case Study: Unconscious Bias Training 145 Opioid Abuse Prevention 70 Data Privacy and Information Security 146 Partnerships for Good: 71 APPENDICES Supporting People Living with Cancer 72 About This Report
    [Show full text]
  • Walgreens Boots Alliance, Inc. 2017 Annual Report
    PART I Item 1. Business Overview Walgreens Boots Alliance, Inc., a Delaware corporation (“Walgreens Boots Alliance”) is the first global, pharmacy-led health and wellbeing enterprise with sales of $118.2 billion in the fiscal year ended August 31, 2017. Our purpose is to help people across the world lead healthier and happier lives. Walgreens Boots Alliance is the largest retail pharmacy, health and daily living destination across the U.S. and Europe. Walgreens Boots Alliance and the companies in which it has equity method investments together have a presence in more than 251 countries and employ more than 385,0001 people. The company is a global leader in pharmacy-led, health and wellbeing retail and, together with the companies in which it has equity method investments, has over 13,2001 stores in 111 countries as well as one of the largest global pharmaceutical wholesale and distribution networks, with over 3901 distribution centers delivering to more than 230,0002 pharmacies, doctors, health centers and hospitals each year in more than 201 countries. In addition, Walgreens Boots Alliance is one of the world’s largest purchasers of prescription drugs and many other health and wellbeing products. Our portfolio of retail and business brands includes Walgreens, Duane Reade, Boots and Alliance Healthcare, as well as increasingly global health and beauty product brands, such as No7, Soap & Glory, Liz Earle, Sleek MakeUP and Botanics. Our global brands portfolio is enhanced by our in-house product research and development capabilities. We seek to further drive innovative ways to address global health and wellness challenges.
    [Show full text]
  • At the Heart of Health Corporate Social Responsibility Report
    2020 At the Heart of Health Corporate Social Responsibility Report #WeAreWBA We are a leading global pharmacy retailer and wholesaler. As a health and well-being enterprise our purpose is to help people across the world lead healthier and happier lives. At the Heart of Health is our annual Corporate Social Responsibility report, covering our CSR initiatives, sustainability progress and Environmental, Social and Governance (ESG) performance for the fiscal year ended Aug. 31, 2020. OVERVIEW HEALTHY PLANET Message from Our Leaders 4 Energy and Emissions 85 Q&A with Our CSR Committee Chair 6 Waste and Plastics 94 Our Vision, Purpose and Values 8 Case Study: Honeybees on Campus 100 At a Glance: WBA 9 SUSTAINABLE MARKETPLACE Highlights and Recognitions 10 Progress Dashboard 12 Sustainability Progress in Our Owned Brands 103 Our Approach to CSR 15 Sourcing 106 CSR Materiality 24 Ingredients, Materials and Traceability 111 Stakeholder Engagement 28 Packaging, Labeling and Transparency 114 Our Response to COVID-19 38 Case Study: Removing Plastics from Boots UK Gift Product Lines 117 Our Response to the Racial Equity Movement 46 Brands with Purpose 118 HEALTHY AND INCLUSIVE WORKPLACE HEALTHY COMMUNITIES Employee Health, Well-being and Safety 123 Access to Affordable and Quality Healthcare 51 Equal Opportunities 134 Health Education and Awareness 61 Case Study: Unconscious Bias Training 145 Opioid Abuse Prevention 70 Data Privacy and Information Security 146 Partnerships for Good: 71 APPENDICES Supporting People Living with Cancer 72 About This Report
    [Show full text]
  • HEALTH + Registered Offi Ce Helping People Look Alliance Boots Gmbh and Feel Their Best Baarerstrasse 94 CH-6300 Zug Switzerland
    Alliance Boots Boots Alliance Annual Report 2010/11 Annual For more information www.allianceboots.com HEALTH + Registered offi ce Helping people look Alliance Boots GmbH and feel their best Baarerstrasse 94 CH-6300 Zug Switzerland Contact [email protected] Alliance Boots Annual Report 2010/11 Overview Our performance in 2010/11 Glossary of key terms (for the year ended 31 March 2011) Constant currency Like for like revenue Trading profit Exchange rates applicable for the financial Like for like revenue on a constant currency basis Profit from operations before amortisation of information for the year ended 31 March 2010. compared to the comparable period in the customer relationships and brands, exceptional previous year. items and share of post tax earnings of EBITDA associates and joint ventures. Trading profit before underlying depreciation Net borrowings Revenue EBITDA Trading profit and amortisation. Cash and cash equivalents, restricted cash, Underlying depreciation and amortisation derivative financial instruments and borrowings Depreciation and amortisation adjusted to Exceptional items net of unamortised prepaid financing fees. exclude amortisation of customer relationships Items classified by Alliance Boots as exceptional and brands and depreciation and amortisation in nature. These are not regarded as forming Net finance costs within exceptional items. +15.1% +10 . 8 % +14 . 2 % part of the underlying trading activities of the Finance costs net of finance income. Group and so merit separate presentation to Underlying net finance costs allow stakeholders to understand the elements Restricted cash Net finance costs adjusted to exclude of financial performance and assess trends in Cash which is restricted for specific purposes exceptional items and timing differences within financial performance.
    [Show full text]
  • Walgreens Boots Alliance, Inc. Common Stock Held by Non-Affiliates (Based Upon the Closing Transaction Price on Such Date) Was Approximately $71.6 Billion
    UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2015 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period From ____________ to ___________ Commission file number 001-36759 WALGREENS BOOTS ALLIANCE, INC . (Exact name of registrant as specified in its charter) Delaware 47-1758322 (State of incorporation) (I.R.S. Employer Identification No.) 108 Wilmot Road, Deerfield, Illinois 60015 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (847) 315-2500 Securities registered pursuant to Section 12(b) of the Act: Title of each class Name of each exchange on which registered Common Stock ($.01 Par Value) The NASDAQ Stock Market LLC 2.875% Notes due 2020 New York Stock Exchange 3.600% Notes due 2025 New York Stock Exchange 2.125% Notes due 2026 New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • KEY FIGURES 2020 Pharmacies and Pharmaceuticals in Norway
    KEY FIGURES 2020 Pharmacies and pharmaceuticals in Norway PHARMACY OWNERSHIP Norwegian pharmacies are mainly run as private enterprises. Only the hospital pharmacies are owned by the public sector (Regional Health Authorities). Nevertheless, the pharmacies are considered part of the Norwegian health service. In 2001, Norway liberalized the pharmacy system. The new legislation led to a great change in ownership – one of the greater changes in the sector’s 400-year history. Since then an increasing portion of pharmacies are owned by pharmacy chains. The four main chains are called Apotek 1, Boots apotek, Vitusapotek and Ditt apotek. To manage a pharmacy, you need the appropriate professional training, including a master’s degree in pharmacy. Three large international pharmacy companies, each vertically integrated with a pharmaceutical wholesaler, own 84 per cent of all pharmacies in Norway. Pharmacy chain Wholesaler Owner Boots Alliance Healthcare Norge AS Walgreens Boots Alliance (USA) Vitusapotek NMD l McKesson Corporation (USA) Apotek 1 Apotek 1 Gruppen AS Phoenix (German) Figure 1: Overview of pharmacy chains, wholesalers and owners in the Norwegian pharmacy market Today the Norwegian pharmacy sector is recognized by: • Free establishment of pharmacies – no establishment criteria • Free ownership of pharmacies – except pharmaceutical manufacturers and doctors • Pharmacy managers must hold a master’s degree in pharmacy • No limit of the number of pharmacies that can be owned by one pharmacy owner – horizontally integrated pharmacy chains are allowed • Vertical integration between wholesalers and pharmacies/ pharmacy chains is allowed As a result of the changes in the Pharmacy Act in 2001, the general public has considerably better accessibility to pharmacies, as the number of pharmacies has increased from 399 in February 2001 to a total of 988 at the end of 2020.
    [Show full text]
  • Case M.9711 - ALLIANCE HEALTHCARE DEUTSCHLAND / GEHE PHARMA HANDEL
    EUROPEAN COMMISSION DG Competition Case M.9711 - ALLIANCE HEALTHCARE DEUTSCHLAND / GEHE PHARMA HANDEL Only the English text is available and authentic. REGULATION (EC) No 139/2004 MERGER PROCEDURE Article 6(1)(b) NON-OPPOSITION Date: 17/08/2020 In electronic form on the EUR-Lex website under document number 32020M9711 EUROPEAN COMMISSION Brussels, 17.08.2020 C(2020) 5738 final PUBLIC VERSION In the published version of this decision, some information has been omitted pursuant to Article 17(2) of Council Regulation (EC) No 139/2004 concerning non-disclosure of business secrets and other confidential information. The omissions are shown thus […]. Where possible the information omitted has been replaced by ranges of figures or a general description. To the notifying party Subject: Case M.9711 – Alliance Healthcare Deutschland AG / GEHE Pharma Handel GmbH Commission decision pursuant to Article 6(1)(b) of Council Regulation No 139/20041 and Article 57 of the Agreement on the European Economic Area2 Dear Sir or Madam, (1) On 10 July 2020, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation by which Alliance Healthcare Deutschland AG (“Alliance”, Germany) acquires sole control of Gehe Pharma Handel GmbH, Gehe Immobilien GmbH & Co. KG and Gehe Immobilien Verwaltungs-GmbH (together “Gehe” or the “Target”, Germany) (the “Transaction”).3 (Alliance is designated hereinafter as the 'Notifying Party' and together with Gehe as the 'Parties'.) 1 OJ L 24, 29.1.2004, p. 1 (the “Merger Regulation”). With effect from 1 December 2009, the Treaty on the Functioning of the European Union (“TFEU”) has introduced certain changes, such as the replacement of “Community” by “Union” and “common market” by “internal market”.
    [Show full text]
  • 1 Alliance Boots Mid-Year Update
    3 November 2009 Alliance Boots mid-year update Following the publication in May of the 2008/09 Annual Review for the year ended 31 March 2009, Alliance Boots today provides a mid-year update covering the six months ended 30 September 2009. Highlights Group • Continuing strong financial performance • Revenue up 11.6% • Andy Hornby joined as Group Chief Executive on 1 July 2009 Health & Beauty Division • Revenue up 6.2% - up 5.4% in constant currency • Boots UK - Revenue up 4.0% - Like for like revenue up 3.4% - Highly successful launch of No7 Protect & Perfect Intense Beauty Serum • Boots Opticians merger with Dollond & Aitchison completed in May 2009 Pharmaceutical Wholesale Division • Revenue up 13.8% - up 6.7% in constant currency • Division-wide business improvement programme progressing well Financing • Robust financial position - £367 million of acquisition borrowings repurchased Group overview Overall the Group continues to perform strongly, with trading in the six months ended 30 September 2009 ahead of our expectations at the time our 2008/09 Annual Review was published. As a result, we are well on track to deliver our 2009/10 operational and financial targets. Outlook We are well positioned for the second half of the year which includes the important Christmas trading period, notwithstanding the weak global economy and the continuing pressures on both governmental and consumer expenditure. We expect our performance to continue to be driven by our transformation and improvement programmes, together with our focus on excellent customer service and our increasingly differentiated product offerings. Stefano Pessina, Executive Chairman, Alliance Boots, said: “I am pleased that Alliance Boots continues to perform strongly, with revenue in the first half of the year up 11.6%, which puts us on track to deliver our 2009/10 targets.
    [Show full text]
  • 00 Cover Vol48.3.Ai 28/9/12 16:21:51
    00 cover vol48.3.ai 28/9/12 16:21:51 2012 Volume 48 Number 3 www.ihf-fih.org World Hospitals and Health Services The Official Journal of the International Hospital Federation C Editorial M Y Health care leadershipp CM Managing the myths of health carre MY Health leadership and manaaggement CY competencies: A systemicc approach CMY K Leadership and globalization: Research in health management education Leadership annd management quality: Key factors in effective health systems Health and hospital reform in Australia – A local heeaalth district’s perspective Please tick your box and pass this on: Current situation of health care in India and corporatization in emerging economies – what is ■ CEO the way forward? ■ Medical director Credentialing for health care leaders: An overview ■ Nursing director of ACHE’s FACHE credential and its contributions to the health care management field ■ Head of radiology Is leadership compatible with hospitals? Lessons ■ Head of physiotherapy from 10 years of teaching leadership to hospital ■ Senior pharmacist managers ■ Head of IS/IT ■ Laboratory director ■ Head of purchasing ■ Facility manager 00-03 - Contents 48_3:33 28/9/12 16:54 Page 1 Global Healthcare Practice Transforming Healthcare Environments The Ingersoll Rand Global Healthcare Practice is leading the way with innovative solutions for the next generation of healthcare facilities. Through solutions and services from RXUOHDGLQJEUDQGVVXFKDV7UDQH6FKODJHDQG,QWHU¾H[ZHDUHGHGLFDWHGWRKHOSLQJ\RX FUHDWHIDFLOLWLHVWKDWFRQWULEXWHWRLPSURYHGRXWFRPHVLQFUHDVHGVDWLVIDFWLRQDQGHQKDQFHG
    [Show full text]
  • Alliance Healthcare CASE STUDY
    ALLIANCE HEALTHCARE CASE STUDY Pharmaceutical and healthcare leader solves project control and health problems at division and country level. A world leading distributor of pharmaceutical and healthcare products implements KeyedInTM Projects to improve project costing, internal recharging and visibility over key project information. Users: 640 Applications: PSA and PPM. About Alliance Healthcare Alliance Healthcare is a leading distributor and wholesaler of various sites which covered project recharging, invoicing and pharmaceutical, medical and healthcare products, offering reporting. This resulted in a disjointed system that lacked innovative added-value services to dispensing points across automation and the processing of information was time– the UK and healthcare manufacturers. consuming and inaccurate. Alliance Healthcare has a strong service-based culture; they are dedicated to working in partnership with pharmacists and Solution manufacturers to improve healthcare in our communities. In order to effectively serve the needs of the business, Alliance Alliance healthcare is a member of Alliance Boots, the leading Healthcare Divisional IT wanted a solution that provided real- international pharmacy-led health and beauty group. time visibility into the status of all key project information. The solution needed to effectively capture all employee time Business Challenge incurred working on projects, this was particularly important for The implementation of KeyedIn Projects was for both Alliance accurate project costing and internal cross charging purposes. Healthcare Divisional IT and country based IT teams. For Divisional IT, the ability to accurately capture internal project information is essential, as small divisional teams of We developed a trusted relationship resources are deployed on projects across Europe; these with our account manager who understood include UK, France, and the Netherlands.
    [Show full text]